Burning Rock Biotech (BNR) Receivables - Net (2019 - 2026)

Burning Rock Biotech's Receivables - Net history runs 8 years deep, the most recent figure standing at $23.8 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 8.52% year-over-year to $23.8 million; the TTM figure through Mar 2026 stood at $23.8 million (up 8.52% YoY), while the FY2025 annual figure was $32.7 million, up 20.72% from the prior year.
• Receivables - Net for Q1 2026 stood at $23.8 million, roughly flat from $23.9 million in the prior quarter.
• The five-year high for Receivables - Net was $26.5 million in Q2 2025, with the low at $14.4 million in Q3 2022.
• The 5-year median for Receivables - Net is $21.1 million (2024), against an average of $20.6 million.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net jumped 79.83% in 2022, then decreased 9.19% in 2023.
• Burning Rock Biotech's Receivables - Net stood at $15.5 million in 2022, then rose by 13.97% to $17.6 million in 2023, then climbed by 20.11% to $21.2 million in 2024, then increased by 13.0% to $23.9 million in 2025, then retreated by 0.28% to $23.8 million in 2026.
• Business Quant data shows BNR's Receivables - Net at $23.8 million in Q1 2026, $23.9 million in Q4 2025, and $25.8 million in Q3 2025.